Scottish Bowel Screening Research Unit, Kings Cross, Clepington Road, Dundee DD3 8EA, UK.
Br J Cancer. 2012 Jul 10;107(2):255-9. doi: 10.1038/bjc.2012.277. Epub 2012 Jun 26.
Randomised trials show reduced colorectal cancer (CRC) mortality with faecal occult blood testing (FOBT). This outcome is now examined in a routine, population-based, screening programme.
Three biennial rounds of the UK CRC screening pilot were completed in Scotland (2000-2007) before the roll out of a national programme. All residents (50-69 years) in the three pilot Health Boards were invited for screening. They received a FOBT test by post to complete at home and return for analysis. Positive tests were followed up with colonoscopy. Controls, selected from non-pilot Health Boards, were matched by age, gender, and deprivation and assigned the invitation date of matched invitee. Follow-up was from invitation date to 31 December 2009 or date of death if earlier.
There were 379 655 people in each group (median age 55.6 years, 51.6% male). Participation was 60.6%. There were 961 (0.25%) CRC deaths in invitees, 1056 (0.28%) in controls, rate ratio (RR) 0.90 (95% confidence interval (CI) 0.83-0.99) overall and 0.73 (95% CI 0.65-0.82) for participants. Non-participants had increased CRC mortality compared with controls, RR 1.21 (95% CI 1.06-1.38).
There was a 10% relative reduction in CRC mortality in a routine screening programme, rising to 27% in participants.
随机试验表明,粪便潜血检测(FOBT)可降低结直肠癌(CRC)死亡率。本研究旨在常规、基于人群的筛查项目中对此结局进行评估。
在全国性计划开展之前,英国 CRC 筛查试验在苏格兰完成了三轮(2000-2007 年)双年度试验。所有(50-69 岁)试点卫生委员会的居民都被邀请参加筛查。他们通过邮件收到 FOBT 检测,在家中完成并寄回分析。阳性检测者接受结肠镜检查。对照组选自非试点卫生委员会,按年龄、性别和贫困程度与受邀者匹配,并分配受邀者的邀请日期。随访从邀请日期开始至 2009 年 12 月 31 日或更早的死亡日期。
每组有 379655 人(中位年龄 55.6 岁,51.6%为男性)。参与率为 60.6%。受邀者中有 961 人(0.25%)死于 CRC,对照组中有 1056 人(0.28%),总 RR 为 0.90(95%CI 0.83-0.99),参与者的 RR 为 0.73(95%CI 0.65-0.82)。与对照组相比,未参与者 CRC 死亡率增加,RR 为 1.21(95%CI 1.06-1.38)。
在常规筛查项目中,CRC 死亡率相对降低了 10%,在参与者中则上升至 27%。